440 related articles for article (PubMed ID: 37481509)
1. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.
Lyu YS; Oh S; Kim JH; Kim SY; Jeong MH
Cardiovasc Diabetol; 2023 Jul; 22(1):185. PubMed ID: 37481509
[TBL] [Abstract][Full Text] [Related]
2. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
3. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
4. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
Kim DJ; Sheu WH; Chung WJ; Yabe D; Ha KH; Nangaku M; Tan EC; Node K; Yasui A; Lei W; Lee S; Saarelainen L; Deruaz-Luyet A; Kyaw MH; Seino Y;
J Diabetes Investig; 2023 Mar; 14(3):417-428. PubMed ID: 36716212
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
[TBL] [Abstract][Full Text] [Related]
7. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
8. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Shi BM
Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Jeon JY; Ha KH; Kim DJ
Diabetes Metab J; 2021 Jul; 45(4):505-514. PubMed ID: 33120439
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):977-83. PubMed ID: 24762119
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis.
Nishimura R; Takeshima T; Iwasaki K; Aoi S
BMJ Open; 2022 Mar; 12(3):e045966. PubMed ID: 35277396
[TBL] [Abstract][Full Text] [Related]
14. Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.
Alkas J; Bosi A; Sjölander A; Barany P; Elinder CG; Fu EL; Carrero JJ
J Nephrol; 2023 Apr; 36(3):705-711. PubMed ID: 36459371
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
Ha KH; Kim DJ; Choi YJ
J Diabetes Investig; 2022 Jun; 13(6):986-996. PubMed ID: 35132815
[TBL] [Abstract][Full Text] [Related]
16. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors.
Zerovnik S; Kos M; Locatelli I
Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus.
Li J; Liu Y; Hao P
Diabetes Res Clin Pract; 2023 Aug; 202():110798. PubMed ID: 37356725
[TBL] [Abstract][Full Text] [Related]
20. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]